Breakpoints25 Loka 2024

#105 – Bringing Positive Vibes Only: Breaking News & Emerging Hypotheses for Gram-Positive Bacterial Infections

Drs. Cesar Arias (@SuperBugDoc) and Katie Barber join Dr. Julie Ann Justo (@julie_justo) to discuss what is hot-off-the-presses for gram-positive bacterial infections and it’s a total party vibe! They review the latest news for recent and ongoing clinical trials (DOTS, DISRUPT, and SNAP trials), discuss hope for novel clinical tests of the cefazolin inoculum effect in staphylococci, and explore the fascinating changes in virulence and potential therapeutic options for the most challenging enterococci.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References

Climate Change and Antimicrobial Resistance. Editors in Conversation Podcast. American Society for Microbiology. Oct 2023.
Is More Better? The Role of Combination Therapy for MRSA. Breakpoints Podcast Episode #30. Society of Infectious Diseases Pharmacists.
Turner NA, et al. DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia. ESCMID Global 2024. April 2024. NCT04775953.
Real-world dalbavancin observational cohort: Rebold N, et al. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. PMID: 38427289.
Exebacase DISRUPT trial : Fowler VG Jr, et al. Clin Infect Dis. 2024 Jun 14;78(6):1473-1481. doi: 10.1093/cid/ciae043. PMID: 38297916.
@snap_trial tweet of Breaking News. Aug 2024.
Investigator Resources for the SNAP trial. Sept 2024: https://www.snaptrial.com.au/for-investigators#interim
Cefazolin inoculum effect on mortality in MSSA bacteremia : Miller WR, et al. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123. PMID: 29977970.
Prevalence of cefazolin inoculum effect in MSSA and modified rapid nitrocefin test for detection: Carvajal LP, et al. Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898-24. PMID: 39345182.
LiaX as surrogate for cell envelope stress in Enterococus faecium: Axell-House DB, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. PMID: 38289081.
Shorter is better for uncomplicated streptococcal bacteremia: Clutter DS, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022024. doi: 10.1128/aac.00220-24. PMID: 38975753.
Short vs. long antibiotic duration in Streptococcus pneumoniae bacteremia: Crotty M, et al. Open Forum Infect Dis. 2024 Aug 30;11(9):ofae478. doi: 10.1093/ofid/ofae478. PMID: 39257675.

This podcast is powered by Pinecast.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(134)

#30 – Is More Better? The Role of Combination Therapy for MRSA

Host Erin McCreary (@erinmccreary) and expert panelists Dr. Katie Barber (@IDKatieBarb), Dr. Warren Rose (@Warren_E_Rose), and Dr. Steven Tong (@syctong) discuss data from early laboratory work to ran...

9 Loka 20201h 1min

#29 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020. Papers discussed: 1) Van Duin D, et al. Lancet Infect Dis. ...

11 Syys 20201h 17min

#28 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) discuss notable infectious diseases publications from the first half of 2020! Papers discussed: 1) Rybak MJ, et al. Am J Health Syst Phar...

4 Syys 20201h 14min

#27 – Expert Updates in Gram Negative Resistance: Q&A Session

This is part 2 of a continuing education series produced in partnership with the SIDP Education Center (SIDPEC) on gram-negative bacterial resistance. It features expert speakers, Drs. Keith Kaye (@Ke...

31 Heinä 20201h 17min

#26 – OPAT - The Final Frontier, Part 2

Gain insight into Outpatient Parenteral Antibiotic Therapy (OPAT) practices across the country from Drs. Jessie Ortwine (@jkortwine), Monica Mahoney (@mmpharmd), Keenan Ryan (@keenanconazole), Monica ...

19 Kesä 202032min

#25 – Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More

Drs. Julie Ann Justo (@julie_justo), Erin McCreary (@erinmccreary), and Helen Newland (@helennewland) discuss ethical allocation of Emergency Use Authorization remdesivir for patients with COVID-19. L...

18 Kesä 20201h 16min

#24 – OPAT – The Final Frontier, Part 1

12 Kesä 202025min

#23 – Taking a “BITE” Out of Antibiotic Prescribing: Strategies to Improve Antimicrobial Usage in Dentistry

Dr. Katie Suda (@sudamonas) and Dr. Erinne Kennedy join Dr. Zahra Escobar (@zkepharmd) of the Breakpoints team to discuss strategies to improve antibiotic utilization and forge connections with our de...

22 Touko 202033min